pyrroles has been researched along with 6-ketoprostaglandin f1 alpha in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busse, R; Falck, JR; Fleming, I; Michaelis, UR; Schmidt, R | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Lui, CY; Martinez, JD; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Asano, M; Harada, N; Mishima, A; Nakayama, T; Nomura, N; Okajima, K; Saito, T | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Birnbaum, Y; Lin, Y; Martinez, JD; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
5 other study(ies) available for pyrroles and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; 8,11,14-Eicosatrienoic Acid; Amino Acid Sequence; Aryl Hydrocarbon Hydroxylases; Carbazoles; Celecoxib; Cells, Cultured; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; DNA, Antisense; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Epoprostenol; Humans; Indoles; Membrane Proteins; Molecular Sequence Data; Morphogenesis; Neovascularization, Physiologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Recombinant Fusion Proteins; RNA, Messenger; Stress, Mechanical; Sulfaphenazole; Sulfonamides; Transcription Factors; Transduction, Genetic; Umbilical Veins | 2005 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2007 |
Atrial natriuretic peptide reduces ischemia/reperfusion-induced spinal cord injury in rats by enhancing sensory neuron activation.
Topics: 6-Ketoprostaglandin F1 alpha; Anilides; Animals; Atrial Natriuretic Factor; Calcitonin Gene-Related Peptide; Capsaicin; Carbazoles; Cells, Cultured; Cinnamates; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indoles; Indomethacin; Male; Neurons, Afferent; Peroxidase; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Spinal Cord; Spinal Cord Diseases; TRPV Cation Channels; Tumor Necrosis Factor-alpha | 2007 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Atorvastatin; Cyclooxygenase 2; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptides; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tyrphostins; Up-Regulation | 2008 |